A bone material composite granule, a manufacturing method and usage method thereof, and a bone cement constructed using the composite granule. The bone material composite granule comprises a co-polymer of a hydroxyethyl methacrylate (HEMA) and methyl methacrylate (MMA) and a calcium phosphate coated on the surface of the co-polymer. A synthesized bone replacement material has improved biocompatibility, bone conduction, and rheological characteristics, and enhanced mechanics and mechanical performance. The bone material can be used in the fields of osteonecrosis, osteoporosis, osteoarthritis, vertebroplasty, bone fracture, bone cyst, alveolar atrophy, subchondral bone defect, subchondral bone cyst, maxillofacial surgery, plastic surgery, minimally invasive procedure, and the like.

A bone material composite granule, a manufacturing method and usage method thereof, and a bone cement constructed using the composite granule. The bone material composite granule comprises a co-polymer of a hydroxyethyl methacrylate (HEMA) and methyl methacrylate (MMA) and a calcium phosphate coated on the surface of the co-polymer. A synthesized bone replacement material has improved biocompatibility, bone conduction, and rheological characteristics, and enhanced mechanics and mechanical performance. The bone material can be used in the fields of osteonecrosis, osteoporosis, osteoarthritis, vertebroplasty, bone fracture, bone cyst, alveolar atrophy, subchondral bone defect, subchondral bone cyst, maxillofacial surgery, plastic surgery, minimally invasive procedure, and the like.

The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein, such as clotrimazole, honokiol, magnolol, tacrolimus, pimecrolimus, sirolimus, everolimus, temsirolimus, spironolactone, fluticasone, fluticasone propionate, fluticasone furoate, linezolid, telmisartan, chlorambucil, retinol, isotretinoin, acitretin, etretinate, retinoic acid (tretinoin), teniposide, mitomycin C, cytarabine, decitabine, vinblastine, vincristine, vindesine, vinorelbine, valrubicin, doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, plicamycin, pazopanib, topotecan, camptothecin, irinotecan, sunitinib, derivatives, or salt thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.

The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein, such as clotrimazole, honokiol, magnolol, tacrolimus, pimecrolimus, sirolimus, everolimus, temsirolimus, spironolactone, fluticasone, fluticasone propionate, fluticasone furoate, linezolid, telmisartan, chlorambucil, retinol, isotretinoin, acitretin, etretinate, retinoic acid (tretinoin), teniposide, mitomycin C, cytarabine, decitabine, vinblastine, vincristine, vindesine, vinorelbine, valrubicin, doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, plicamycin, pazopanib, topotecan, camptothecin, irinotecan, sunitinib, derivatives, or salt thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.

The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein, such as clotrimazole, honokiol, magnolol, tacrolimus, pimecrolimus, sirolimus, everolimus, temsirolimus, spironolactone, fluticasone, fluticasone propionate, fluticasone furoate, linezolid, telmisartan, chlorambucil, retinol, isotretinoin, acitretin, etretinate, retinoic acid (tretinoin), teniposide, mitomycin C, cytarabine, decitabine, vinblastine, vincristine, vindesine, vinorelbine, valrubicin, doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, plicamycin, pazopanib, topotecan, camptothecin, irinotecan, sunitinib, derivatives, or salt thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.

The invention features biodegradable materials, and in vitro and in vivo methods of using such compositions to promote bone and soft tissue growth and healing.

The invention features biodegradable materials, and in vitro and in vivo methods of using such compositions to promote bone and soft tissue growth and healing.

The invention features biodegradable materials, and in vitro and in vivo methods of using such compositions to promote bone and soft tissue growth and healing.

A method for preparing a degradable magnesium-containing calcium phosphate-calcium sulfate porous composite biological scaffold by subjecting a calcined bovine cancellous bone mineral porous scaffold to a treatment using a ternary system containing a magnesium source, a sulfur source and a phosphorus source, taking out and drying, and subjecting to a high-temperature calcination. The degradable magnesium-containing calcium phosphate-calcium sulfate porous composite biological scaffold has good three-dimensional interconnected mesh structure, osteoconductivity, degradability, good mechanical strength and biocompatibility, simultaneously. At the same time, calcium sulfate whiskers with larger length-diameter ratio grow in the mesh, thereby increasing the specific surface area of the material and possibly improve the adhesion of cells. The composite biological scaffold may have potential osteoinductivity due to the effective addition of the osteogenic active ionized magnesium and the calcium sulfate which can produce a local high-calcium environment when degraded.

Provided are gene-activated materials comprising a scaffold and at least one nucleic acid molecule which may be chemical bound together or in which the at least one nucleic acid is not bound but coated on a surface of the scaffold. Methods for regenerating bone using these gene-activated materials are also provided.